• 1
    Silman AJ, Hochberg MC (2001) Epidemiology of the rheumatic diseases, 2nd edn. Oxford University Press, Oxford.
  • 2
    Van Halm V, Peters M, Voskuyl A et al. (2009) Rheumatoid arthritis versus diabetes as a risk factor for cardiovascular disease: a cross-sectional study, the CARRE Investigation. Ann Rheum Dis 68, 1395400.
  • 3
    Choy E, Sattar N (2009) Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions. Ann Rheum Dis 68, 4609.
  • 4
    Boers M, Nurmohamed M, Doelman C et al. (2003) Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis. Ann Rheum Dis 62, 8425.
  • 5
    Greenberg J, Kremer J, Curtis J et al. (2011) Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis 70, 57682.
  • 6
    Munro R, Morrison E, McDonald A, Hunter J, Madhok R, Capell H (1997) Effect of disease modifying agents on the lipid profiles of patients with rheumatoid arthritis. Ann Rheum Dis 56, 3747.
  • 7
    Kitas G, Gabriel S (2011) Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives. Ann Rheum Dis 70, 814.
  • 8
    Sattar N, McCarey D, Capell H, McInnes I (2003) Explaining how “High-Grade” systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 108, 295763.
  • 9
    Snow M, Mikuls T (2005) Rheumatoid arthritis and cardiovascular disease: the role of systemic inflammation and evolving strategies of prevention. Curr Opin Rheum 17, 23441.
  • 10
    Kaplan M (2006) Cardiovascular disease in rheumatoid arthritis. Curr Opin Rheum 18, 28997.
  • 11
    Van Doornum S, McColl G, Wicks I (2004) Atorvastatin reduces arterial stiffness in patients with rheumatoid arthritis. Ann Rheum Dis 63, 15715.
  • 12
    McCarey D, McInnes I, Madhok R et al. (2004) Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 363, 201521.
  • 13
    Stavropoulos-Kalinoglou A, Metsios G, Panoulas V et al. (2009) Associations of obesity with modifiable risk factors for the development of cardiovascular disease in patients with rheumatoid arthritis. Ann Rheum Dis 68, 2425.
  • 14
    Dessein P, Joffe B, Veller M et al. (2005) Traditional and non-traditional cardiovascular risk factors are associated with atherosclerosis in rheumatoid arthritis. J Rheumatol 32, 43542.
  • 15
    Bjornadal L, Brandt L, Klareskog L, Askling J (2006) Impact of parental history on patients' cardiovascular mortality in rheumatoid arthritis. Ann Rheum Dis 65, 7415.